GeneDx Holdings (WGS) Operating Expenses (2020 - 2026)

GeneDx Holdings has disclosed Operating Expenses across 7 years of filings, most recently posting $94.4 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 49.77% year-over-year to $94.4 million; the TTM figure through Mar 2026 stood at $272.5 million (up 52.87% YoY), while the FY2025 annual figure was $222.8 million, up 48.33% from the prior year.
• Operating Expenses improved to $94.4 million in Q1 2026, from $71.4 million in the prior quarter.
• Over the last five years, Operating Expenses for WGS reached as high as $98.5 million in Q2 2022 and fell as low as $35.0 million in Q1 2024.
• The 5-year median for Operating Expenses is $58.3 million (2023), against an average of $58.0 million.
• The widest YoY moves for Operating Expenses: up 296.8% in 2022, down 56.17% in 2022.
• A 5-year view of Operating Expenses shows it stood at $67.6 million in 2022, then plunged by 34.68% to $44.1 million in 2023, then fell by 10.01% to $39.7 million in 2024, then jumped by 79.67% to $71.4 million in 2025, then soared by 32.26% to $94.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $94.4 million, $71.4 million, and $64.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.